DE602006016014D1 - Kombination aus triazinderivaten und insulin-sensibilisatoren - Google Patents

Kombination aus triazinderivaten und insulin-sensibilisatoren

Info

Publication number
DE602006016014D1
DE602006016014D1 DE602006016014T DE602006016014T DE602006016014D1 DE 602006016014 D1 DE602006016014 D1 DE 602006016014D1 DE 602006016014 T DE602006016014 T DE 602006016014T DE 602006016014 T DE602006016014 T DE 602006016014T DE 602006016014 D1 DE602006016014 D1 DE 602006016014D1
Authority
DE
Germany
Prior art keywords
sensitivators
insulin
combination
triazine derivatives
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006016014T
Other languages
German (de)
English (en)
Inventor
Gerard Moinet
Daniel Cravo
Didier Mesangeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of DE602006016014D1 publication Critical patent/DE602006016014D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006016014T 2006-01-13 2006-12-18 Kombination aus triazinderivaten und insulin-sensibilisatoren Active DE602006016014D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
PCT/EP2006/012185 WO2007079917A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers

Publications (1)

Publication Number Publication Date
DE602006016014D1 true DE602006016014D1 (de) 2010-09-16

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006016014T Active DE602006016014D1 (de) 2006-01-13 2006-12-18 Kombination aus triazinderivaten und insulin-sensibilisatoren

Country Status (22)

Country Link
US (2) US8791115B2 (cg-RX-API-DMAC10.html)
EP (1) EP1971330B1 (cg-RX-API-DMAC10.html)
JP (1) JP5249782B2 (cg-RX-API-DMAC10.html)
KR (2) KR20140033498A (cg-RX-API-DMAC10.html)
CN (1) CN101355933A (cg-RX-API-DMAC10.html)
AR (1) AR059032A1 (cg-RX-API-DMAC10.html)
AT (1) ATE476179T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334734B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620985B8 (cg-RX-API-DMAC10.html)
CA (1) CA2640897C (cg-RX-API-DMAC10.html)
CY (1) CY1110789T1 (cg-RX-API-DMAC10.html)
DE (1) DE602006016014D1 (cg-RX-API-DMAC10.html)
DK (1) DK1971330T3 (cg-RX-API-DMAC10.html)
EA (1) EA015576B1 (cg-RX-API-DMAC10.html)
ES (1) ES2347177T3 (cg-RX-API-DMAC10.html)
FR (1) FR2896159B1 (cg-RX-API-DMAC10.html)
IL (1) IL192558A (cg-RX-API-DMAC10.html)
PL (1) PL1971330T3 (cg-RX-API-DMAC10.html)
PT (1) PT1971330E (cg-RX-API-DMAC10.html)
SI (1) SI1971330T1 (cg-RX-API-DMAC10.html)
WO (1) WO2007079917A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806947B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
JP5485292B2 (ja) 2008-12-12 2014-05-07 ポクセル・エスアーエス Ampk活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
ES2530223T3 (es) 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第2型糖尿病之治療
KR20120011667A (ko) 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) * 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU5745601A (en) * 2000-05-01 2001-11-12 Aeropharm Technology Inc A core formulation
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
WO2005012243A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
BRPI0620985B1 (pt) 2020-04-28
PT1971330E (pt) 2010-09-09
US8791115B2 (en) 2014-07-29
CA2640897A1 (en) 2007-07-19
WO2007079917A2 (en) 2007-07-19
DK1971330T3 (da) 2010-10-25
AR059032A1 (es) 2008-03-12
US20100285117A1 (en) 2010-11-11
IL192558A (en) 2013-04-30
CN101355933A (zh) 2009-01-28
KR20080088630A (ko) 2008-10-02
CY1110789T1 (el) 2015-06-10
EA015576B1 (ru) 2011-10-31
CA2640897C (en) 2015-10-20
AU2006334734A1 (en) 2007-07-19
EP1971330B1 (en) 2010-08-04
AU2006334734B2 (en) 2012-07-19
ATE476179T1 (de) 2010-08-15
JP2009523142A (ja) 2009-06-18
KR20140033498A (ko) 2014-03-18
JP5249782B2 (ja) 2013-07-31
SI1971330T1 (sl) 2010-11-30
WO2007079917A3 (en) 2007-08-30
BRPI0620985B8 (pt) 2021-05-25
PL1971330T3 (pl) 2011-01-31
EA200801676A1 (ru) 2008-12-30
BRPI0620985A2 (pt) 2011-11-29
EP1971330A2 (en) 2008-09-24
FR2896159B1 (fr) 2008-09-12
ES2347177T3 (es) 2010-10-26
ZA200806947B (en) 2009-11-25
FR2896159A1 (fr) 2007-07-20
KR101482685B1 (ko) 2015-01-14
US20140050786A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
DK1984322T3 (da) Benzamid- og heteroarenderivater
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
ATE511509T1 (de) Azaindolylverbindungen und anwendungsverfahren
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
DK2049614T3 (da) Keramisk proppant med lav vægtfylde
IL210412A0 (en) Heterocyclic derivatives and uses thereof
HRP20151052T1 (xx) Peteroäślani heterocikliäśki amidi i srodne tvari
EP2116535A4 (en) GLUCOKINASE ACTIVATING SUBSTANCE
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
SI2046324T1 (sl) Zdravljenje in preventiva mukozitisa z derivati antocianidina
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2066174A4 (en) COMPOSITIONS WITH ALPHA-1-ANTITRYPINE AND METHOD OF USE THEREOF
ZA200806947B (en) Combination of triazine derivatives and insulin sensitisers
DK2084207T3 (da) Stabile laktidpartikler
BRPI0719228A2 (pt) Composição estabilizada de prostaglandina e
EP2275433A4 (en) METASTINE DERIVATIVE AND USE THEREOF
IL196469A0 (en) New medical use of triazine derivatives
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica
AT508430A5 (de) Formbauteil und dessen verwendung
EP2165712A4 (en) PROCYANIDINE, PROPELARGONIDINE AND PRODELPHINIDINE CONTAINING MENDELHAUT PHENOLEXTRACTS
BRPI1011318A2 (pt) derivados de triazina e suas aplicações terapêuticas
DE102007013751B8 (de) Tiefpassfilter und Tiefpassfilter-Anordnung
ATE540682T1 (de) Kombination von triazin-derivaten und insulin- sekretionsstimulatoren